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ABSTRACT
Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kid-
ney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding 
nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, 
thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years 
brought development of innovative immunotherapy combinations as a method for improving immunotherapy 
efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment 
with nivolumab.
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Introduction
Rare cases of spontaneous complete remissions 
due to potential immunological anti-tumour responses 
have been drawing the attention of researchers for cen-
turies. Well-documented cases of attempts at inducing 
such response have been undertaken as early as in the 
17th and 18th centuries. Back then, spontaneous remis-
sion was most commonly seen along with severe infec-
tion. Nineteenth century research led to the formulation 
of the first standardised therapies based on attenuated 
encapsulated bacteria [1]. However, it was only the de-
velopments in molecular biology in the second half of 
the 20th century that brought about the opportunity to 
develop a modern immunotherapeutic approach, with 
its rapid expansion during the last decade. 
According to the Global Cancer Observatory report, in 
2018 about 400 thousand new renal cell carcinoma (RCC) 
cases were diagnosed worldwide, with over 175 thousand 
RCC-related deaths [2]. The progress in RCC treatment 
seen in the 21st century is based on the understanding of 
RCC core pathomechanisms: induction of angiogenesis 
and deregulation of immune response (overactivation 
of innate inflammatory response with deficient adaptive 
immune response). Several new therapeutic approaches 
for advanced disease have been developed: inhibitors of 
vascular endothelial growth factor (VEGF)-dependent 
angiogenesis; inhibitors of mammalian target of rapa-
mycin (mTOR) — an another protein involved in RCC 
pathogenesis; cytokines that induce adaptive response; 
and finally the immune checkpoint inhibitors — innovative 
particles that activate suppressed mechanism of antigen 
presentation and enable cytotoxic T-cell activity.
Nivolumab is one of the first immune checkpoint 
inhibitors. Clinical phase of its’ development began in 
2006 [3] and the drug gained first registration label in 
the 2014. Currently, as of December 2018, nivolumab 
is approved in Europe in six indications: melanoma, 
non-small cell lung cancer, renal cell carcinoma, urothe-
lial cancer, squamous cell cancers of head and neck, and 
classic Hodgkin lymphoma. 
The presented article aims at providing practicing 
oncologists with current data regarding the activity and 
safety profile of nivolumab in the treatment of RCC as 
well as valuable insights into clinical aspects of immune 
response in the pathophysiology of RCC.
Immune system and carcinogenesis
The immune system plays an important and multi-
factorial role in the aetiopathogenesis of cancer. From 
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the one side, some aspects of immune response may 
promote carcinogenesis, enabling survival of cancer cells 
in a metastatic niche or leading to inefficient protein 
and energy metabolism. From the other side, the im-
mune system is the most important defence line against 
cancer development.
We currently know that immune cells from myeloid 
and lymphatic lines, both present in direct tumour mi-
croenvironment as well as distant ones, are responsible 
for several characteristic traits of cancer called “hall-
marks of cancer”. These arise through several feedback 
loops: stimulation of proliferation; resistance to antipro-
liferative signalling; evasion of apoptosis; induction of 
angiogenesis; local invasion and metastases formation; 
and escape from immunosurveillance (Table 1) [4]. Ad-
ditionally, overactivation of nonspecific inflammatory 
response is an important driver of cachexia, one of the 
most common cancer complications.
Immunosurveillance and mechanisms responsible 
for evasion from it are among the key factors in onco-
logy [5]. Adaptive antitumour immune response requires 
a difference in antigens between cancer and healthy 
tissue. These so-called neoantigens are released from 
the cancer cell and then captured and presented to the 
immune system by dendritic cells (DC). For proper 
functioning, DCs have to go through a process of activa-
tion and maturation, which enable expression of specific 
co-stimulatory factors required by naïve T cells (Tn). If 
a mature DC presents detected antigen within proper 
major histocompatibility complex (MHC) class I and II 
and with adequate co-stimulation, antigen-specific Tn 
are selected and activated. As a result, Tn differentiate 
and proliferate into cytotoxic (Tc) and memory (Tm) 
clones. 
Activated Tc clone have to reach cancer tissue and 
infiltrate it. Cancer cell destruction requires Tc cell to re-
cognize it's specific antigen, presented through class I MHC, 
in the absence of additional signals supressing cytotoxicity 
(either by cytokines or immunosuppressive cell-membrane 
molecules present in the tumour microenvironment). 
Destroyed cancer cells release new portions of 
neoantigens, again detected and presented by DC, 
closing the cycle of immune antitumour response 
(Fig. 1) [6]. Each cycle iteration may promote additional 
clones of Tc lymphocytes active against subsequent 
neoantigens, potentially resulting in more and more 
effective response.
It is well acknowledged that evasion from immu-
nosurveillance through disruption of at least one part 
of the described cycle is a nacessary condition for the 
cancer to develope. To achieve effective and persistent 
tumour control by the immune system — and there-
fore long-term remission — we have to facilitate closing 
of the cycle. This requires recognition of its weak spots 
and potential methods for strenghtening them.
Selected mechanisms of 
immunosurveillance evasion  
— clinical aspects
Systematic review of mechanisms used by cancer 
to evade immunosurveillance surpasses the limits of 
this manuscript. An excerpt of this complex landscape, 
significant in terms of the immune feedback loop de-
scribed above, is presented in Table 2. Analysis of the 
aforementioned mechanisms at each stage of cytotoxic 
antitumour immune response provide practical insights 
Table 1. Mechanisms promoting carcinogenesis with leukocyte involvement [4]
Cancer trait Selected responsible mechanisms 
Continuous stimulation of 
proliferation
Direct production of growth factors (EGF, TGF, TNF, FGF, PDGF)
Releasing growth factors bound to stroma
Resistance to antiproliferative 
signalling
Induction of HIF, HSP, and b-catenin production
Decreasing expression of adhesive molecules
Evasion of cell death Stimulation of survival-related pathways (VCAM-1)
Chemotherapy resistance related to cathepsin concentration
Angiogenesis induction Releasing of proangiogenic factors: VEGF, PDGF, TNF-a, Ang-2
Local invasion and metastasis Stroma proteolysis
Suppression of adhesive molecules functions
Increasing endothelium permeability
Generation of pre-metastatic niche
Immunosurveillance evasion Depletion of cytotoxic cells
Stimulation of suppressor Treg lymphocyte proliferation
Promotion of mechanism leading to immunological toleration
Ang-2 — angiopoetyna-2; EGF — epithelial growth factor; FGF — fibroblast growth factor; HIF — hypoxia induced factor; HSP — heat-shock protein; PDGF 
— platelet-derived growth factor; TGF — transforming growth factor; TNF — tumour necrosis factor; Treg — lymphocytes T-regulatory; VCAM — vascular 
cell adhesion molecule; VEGF — vascular endothelial growth factor
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7. Destruction 
of cancer cells 
by Tc lymphocytes 
and other immune
cells 
1. Cancer
 cell death 
— releasing 
of antigens
2. Presentation 
of tumor antigens 
(dendriticcells/ 
/otherAPC)
3. Priming and 
activation (DC, Tn) 
 
— differentiation 
in Tc lymohocytes
4. Migration 
of Tc lymphocytes 
to tumors
5. Infiltration of tumor 
by Tc lymphocytes 
(role of 
epithelial cells)
6. Recognition 
of cancer cells 
by Tc lymphocytes
Figure 1. Cycle of immunological antineoplastic response (based on [6]). APC — antigen-presenting cells; DC — dendritic cells; 
Tn — lymphocytes T-naïve; Tc — lymphocytes T-cytotoxic
Table 2. Mechanisms impacting different stages of immunosurveillance [6, 11, 34, 35]
Stage Mechanisms impairing  
immunosurveillance
Mechanisms promoting 
immunosurveillance
1. Cancer cell death 
— release of antigens
Low cell antigenicity (low TMB)
Non-immunogenic cell death
High cell antigenicity (high TMB, mutagens)
Immunogenic cell death
2. Neoantigen presentation Immunosuppressive cytokines (IL-10; IL-4; IL-13)
Low DC availability
Activating cytokines (TNF-a, IL-1, IFN-a)
PRR activation (DAMPs, PAMPs) 
3. Priming and Tn activation 
— differentiation in Tc
Suppressive co-stimulation (CTLA4:B7.1;  
PD-L1:PD-1; PD-L1:B7.1)
Suppressive cytokines — prostaglandins 
Availability and variability of Tn
Treg
Activating co-stimulation (CD28:B7.1; 
OX40:OX40L; CD27:CD70)
Activating cytokines (IL-2; IL-12) 
4. Migration of Tc Chemokines engaging Treg and MDSC Chemokines engaging Tc (CCL2; CCL3; CCL4; 
CCL5; CXCL9; CXCL10)
5. Tumour Tc infiltration Angiogenesis (especially VEGF-dependent) Adhesive particles (ICAM1, selectins)
6. Cancer cell recognition 
by Tc
Low cell antigenicity (low TMB)
Decreased expression of MHC
Low number of Tc clones
High cell antigenicity
Proper TCR expression
High affinity of TCR to antigen
7. Destruction of cancer cell 
by Tc and other immune cells
Immunosuppressive co-stimulation  
(PD-L1:PD-1; PD-L1:B7.1; MICA:MICB; BTLA; LAG-3)
TNF-b
IFN-g
BTLA — B- and T-lymphocyte attenuator; CCL — CC class chemokine; CTLA4 — cytotoxic lymphocyte antigen-4; CXCL — CXC class chemokine; DAMPs — dam-
age associated molecular patterns; IFN — interferon; IL — interleukin; LAG-3 — lymphocyte-activating gene (protein product of its’ transcription); MDSC 
— myeloid-derived suppressor cell; MHC — major histocompatibility complex; PAMPs — pathogen associated molecular patterns; PD-1 — programmed cell 
death 1 receptor; PD-L1 — programmed cell death 1 receptor ligand; PRR — pattern-recognizing receptor; Tc — T-cytotoxic lymphocyte; TCR — T lymphocyte 
receptor; TMB — tumour mutational burden; Tn — T-naïve lymphocytes; TNF — tumour necrosis factor; Treg — T-regulatory lymphocyte; VEGF — vascular 
endothelial growth factor
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into the mechanism of action of novel therapeutic ap-
proaches. Below we describe those that are most impor-
tant to understand the clinical application of immune 
checkpoint inhibitors. 
Expression of programmed death receptor 1 (PD-1) 
is present mostly on mature Tc lymphocytes. Interaction 
of PD-1 with specific ligands, PD-L1 and PD-L2, sup-
presses cytotoxic activity of lymphocytes. Several signal-
ling pathways, existing in the tumour microenvironment, 
induce expression of PD-1 ligands on the surface of 
different types of cells present in the microenvironment 
because the interaction between PD-1 and PD-L1/2 is 
a common mechanism behind immunosurveillance eva-
sion [7, 8]. Nivolumab acts through the inhibition of 
this signalling. Additionally, PD-1 might play a role in 
the activation of Tn lymphocytes by DC, but available 
data suggest that this effect is not crucial for immune 
checkpoint inhibitor effectiveness. 
Immunogenicity of cancer cells can be assessed in two 
categories: quantity and quality of neoantigens present in 
the cancer cell and the actual availability of neoantigens 
for DC. Tumour mutational burden (TMB), defined as 
the number of mutations per thousand DNA base pairs, 
is a rising biomarker for immunogenicity prediction. The 
more mutations, the more altered proteins and therefore 
the more neoantigens. Several reports confirm the predic-
tive value of TMB for immunotherapy effectiveness, in 
terms of both overall survival and depth of response [9, 10].
The second factor defining immunogenicity of cancer 
cells is the actual availability of its neoantigens for DC 
and Tc cells. This depends on several factors, including: 
MHC expression; expression of neoantigens themselves; 
mechanisms of cancer cell death and its effective (im-
munogenic death) or non-effective (non-immunogenic 
death) neoantigen release [11]. 
Therapeutic influence on TMB is not yet available, 
but the strategy of combining immune checkpoint in-
hibitors with therapies aimed at increasing neoantigen 
expression and inducting immunogenic cancer cell death 
are intensively studied [12]. One of most successful ap-
proaches, often described in the literature, is the combi-
nation of immunotherapy with radiotherapy, especially 
valuable in oligometastatic diseases or in the presence 
of tumours in difficult localisations [13–15]. Practicing 
oncologists should be aware of numerous clinical trials 
evaluating the combination of immunotherapy with 
other drugs, including chemotherapy, and about the 
potentially beneficial role of palliative radiotherapy in 
patients receiving immune checkpoint inhibitors (these 
data, although arising from low numbers of cases or 
singular case reports, are extremely promising).
Antigen presentation by DC and recruitment of Tn 
lymphocytes are, besides the cytotoxic response itself, 
part of one of the two main phases of immune response 
activated by immune checkpoint inhibitors. This com-
plex mechanism will not be fully covered, but some of 
its aspects have strong implications for clinical practice. 
Dendritic cells, in order to efficiently stimulate Tc clone 
proliferation, have to go properly through the activation 
and maturation processes. Presentation of antigens by 
non-activated DC fails to recruit Tn or, even worse, 
recruitment of Tn simultaneously with additional signal-
ling through co-stimulatory molecules may be responsi-
ble for inducing immune tolerance. 
Maturation of dendritic cells requires the coexistence 
of several signals. From a functionary perspective, we 
can divide them into two groups: cytokines and ligands 
of pattern-recognising receptors (PRR). PRR ligands 
include damage-associated molecular patterns (DAMPs) 
and pathogen-associated molecular patterns (PAMPs). 
DAMPs are mostly products of cell lysis and stroma 
damage: HSP, calreticulin, nucleic acids, and products of 
their degradation. PAMPs are mostly substances being 
common denominators of pathogenic microorganisms, 
such as evolutionary conservative parts of bacterial cell 
wall or viral RNA. DAMPs and PAMPs circulate in 
blood in the presence of tissue damage or infection and 
are a warning signal required for initiation of DC matura-
tion. Lack of proper PRR stimulation dampens activation 
of cellular response, preventing auto-immunogenicity in 
normal conditions but concurrently allowing evasion of 
immunosurveillance during oncogenesis [16].
Gut microbiome is a significant source of PAMPs, 
which draws attention to the connection between gut 
microbiome, immunological response, and carcino-
genesis. Beside its effect on DC maturation, several 
mechanisms of interaction between gut microbiome, 
and cellular and inflammatory response have been de-
scribed. Numerous reports tie phenotype of commensal 
microbiota with effectiveness of immunotherapy — both 
in animal models and in humans [17–21]. Connecting 
negative impact of antibiotics on bacterial microflora, 
additional reports showed strong negative correlation 
between antibiotics administration and effectiveness 
of immune checkpoint inhibitors. Significantly worse 
outcomes of checkpoint inhibitor therapy (both overall 
survival [OS] and progression-free survival [PFS]) was 
shown in patients pretreated with antibiotics as com-
pared to patients not exposed to antibiotics (Table 3). 
Oncologists administering immunotherapy should be 
aware of this connection and avoid needless antibio-
tics. This includes adequate differential diagnosis be-
tween infections and autoimmunological adverse events 
associated with immunotherapy (e. g. bacterial pneumo-
nitis vs. autoimmunological pneumonitis; Clostridium dif-
ficile infection vs. autoimmunological colitis). Available 
data do not support attempts to modify the composition 
of gut microbiome in patients outside of clinical trials. 
Cachexia is a multifactorial disease that includes 
protein and energy malnutrition in mechanisms of both 
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Table 3. Publication connecting antibiotics (ATB) with response to immune checkpoint inhibitors
Author, reference Cancer type N Type of drug mPFS  
(ATB+ vs. ATB–)
mOS  
(ATB vs. ATB–)
Derosa et al. 2018 [36] mRCC 121 anti-PD-L1 1.9 vs. 7.4 months 
(p < 0.01)
17.3 vs. 30.6 months 
(p = 0.03)
Derosa et al. 2018 [36] mNSCLC 239 anti-PD-L1 1.9 vs. 3.8 months 
(p = 0.03)
7.9 vs. 24.6 months 
(p < 0.01)
Thompson et al. 2017 [37] mNSCLC 74 anti-PD-1 2.0 vs. 3.8 months 
(p < 0.001)
4.0 vs. 12.6 months 
(p = 0.005)
Huemer et al. 2018 [38] mNSCLC 30 anti-PD-1 2.9 vs. 3.1 months 
(p = 0.031)
11.1 vs. 15.1 months 
(p = 0.023)
Routy et al. 2018 [20] mRCC, mUC 
mNSCLC, 
249 anti-PD-1;  
anti-PD-L1
3.5 vs. 4.1 months 
(p = 0.017)
11.5 vs. 20.6 months 
(p < 0.001)
Tinsley et al. 2018 [39] mMM, mRCC, 
mNSCLC
303 anti-PD-1;  
anti-PD-L1
3.2 vs. 5.8 months 
(p = 0.049)
10.4 vs. 22.4 months 
(p = 0.001)
mRCC — metastatic renal cell carcinoma; mNSCLC — metastatic non-small cell lung cancer; mUC — metastatic urothelial cancer; ATB — antibiotics; mPFS 
— median progression-free survival; mOS — median overall survival
inadequate intake and excessive expenditure, non-spe-
cific systemic inflammation and increased catabolism. 
Cachexia develops in 80% of cancer cases and is the lead-
ing cause of death in nearly 20% of cancer patients. The 
incidence and intensity of cachexia are related to stage of 
disease and cancer biology. Cachexia develops commonly 
in patients with gastric, pancreatic, and lung cancers as 
well as in patients with genitourinary, lymphatic and gy-
naecological malignancies [22]. The presence of cachexia 
is a factor associated with poor prognosis.
Additionally, cachexia is a negative prognostic 
factor for immune checkpoint therapy in animal 
models and in human clinical trials [23, 24]. This may 
be due to promotion of immunosurveillance evasion 
through the following: induction of immunosup-
pression (interleukin-6 [IL-6], glucocorticosteroids, 
depletion of immune cells); limitation of metabolic 
support for highly-energetic processes associated 
with Tc clone activation; and increase in clearance 
of therapeutic monoclonal antibodies due to protein 
deficiency [25]. 
Despite common knowledge regarding the benefits 
of treating cachexia — mostly through adequate nutri-
tional support [26] — we lack prospective data that allow 
optimisation of cachexia management in patients under-
going immune checkpoint therapy. Although promising 
interventions exist (e.g. non-steroidal anti-inflammatory 
drugs, direct and indirect IL-6 antagonists), their com-
bination with immune checkpoint inhibitors remains 
a domain of research. Oncologists should be aware of 
decreased immunotherapy effectiveness in patients with 
cachexia (alternative therapies might be advised), and 
they should recognise that immune response requires 
a significant amount of energy and thus treat cachexia 
intensively according to current guidelines.
Nivolumab in renal cell carcinoma 
refractory to antiangiogenic treatment
In November 2015 nivolumab gained registration 
by Food and Drug Administration (FDA) in the USA 
and in April 2016 by the European Medicine Agency 
(EMA) in the indication “treatment of advanced renal 
cell carcinoma in patients who received prior treat-
ment”. The registration was based on the results of 
the phase III trial CheckMate 025 (NCT01668784) 
trial. This international study recruited adult patients 
with advanced RCC after failure of one or two lines of 
antiangiogenic treatment. Between October 2012 and 
March 2014, 821 patients were randomised to either 
nivolumab at a dose of 3 mg/kg body weight biweekly 
or everolimus in standard continuous dosing of 10 mg 
per day (Fig. 2) [27].
The newest, three-year update of the study results 
[28] showed data after a median observation time of 
24 months in the nivolumab arm and 19 months in 
the everolimus arm (Table 4). The response rate was, 
respectively, 26% and 5%, although nearly 35% of 
patients receiving nivolumab were refractory to the 
treatment and had progressive disease as their best 
response. Typically for the immunotherapy, not all 
responses were seen in the first scanning, and some 
were obtained later. Median OS was 25.8 months in the 
nivolumab arm and 19.7 months in the everolimus arm 
(hazard ratio [HR] 0.74; p = 0.0005). Rates of two-year 
survival were, respectively, 52% and 42%, and rates of 
three-year survival were 39% and 30%, respectively. Me-
dian progression-free survival times (4.2 vs. 4.5 months) 
and median duration of response (12.3 vs. 12.0 months) 
did not differ between patients receiving nivolumab and 
everolimus, respectively. Durable responses were more 
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Table 4. Summary of CheckMate025 trial
Nivolumab Everolimus
ORR (CR+PR) 26% 5%
mPFS 4.2 months 4.5 months
mOS 25.8 months 19.7 months
2-year survival rate 53% 42%
3-year survival rate 39% 30%
Rate of G1–4 toxicity 80% 89%
Rate of G3–4 toxicity 21% 37%
ORR — objective response rate; CR — complete response; mOS — median overall survival; mPFS — median progression-free survival; PR — partial response
Everolimus 10 mg/day p.o. 
administerd continously 
(n = 411) 
Nivolumab 3 mg/kg i.v. 
every 2 weeks 
(n = 410) • mRCC with clear cell component 
• KPS ≥ 70% 
• 1–2 prior antiangiogenic therapies 
• Progression within 6 months prior 
   to enrollment 
Figure 2. Scheme of CheckMate025 trial. mRCC — metastatic renal cell cancer; KPS — Karnofsky Performance Status 
common in patients receiving nivolumab (18% vs. 6%). 
Toxicity profile was also in favour of nivolumab, with 
a rate of all treatment-related adverse events of 80% in 
the nivolumab arm and 89% in the everolimus arm with 
grade 3–4 adverse events present in, respectively, 21% 
and 37% of patients.
In the subgroup analysis [29] the benefit from 
nivolumab was irrespective of either MSKCC or IMDC 
prognostic group, number of prior treatment lines, and 
localisation of metastases. The only subgroup of patients 
with limited benefit from nivolumab were patients aged 
over 75 years. A trend in favour of nivolumab was seen in 
subgroups of patients with lung metastases and without 
bone or liver metastases. 
Choice of optimal therapy after 
progression of anti-VEGF TKI  
— the place of nivolumab
In Poland, majority of patients with advanced 
RCC treated outside of clinical trials receive tyrosine 
kinase inhibitors (sunitinib or pazopanib) as a first-line 
therapy. The median progression-free survival 
achieved with TKI reaches 9–11 months [30, 31], and 
second-line treatment is inevitable in the majority of 
patients. In this setting options include the following: 
alternative TKI with a different affinity to key recep-
tors (axitinib); mTOR inhibitor (everolimus); multi-
kinase inhibitor with additional activity against MET 
and AXL kinases (cabozantinib); and immune check-
point inhibitors aimed at PD-1 (nivolumab). Only 
some of these options were compared head-to-head 
in randomised clinical trials, yet knowledge regarding 
different modes of action, expected efficiency, and 
toxicity profile allows optimisation of therapy for each 
patient (Table 5).
In an indirect comparison of response rates, both 
nivolumab and cabozantinib exhibit similar activity (25% 
vs. 5% for, respectively, nivolumab and everolimus in the 
CheckMate 025 trial and 17% vs. 3% for, respectively, 
cabozantinib and everolimus in the METEOR trial). 
However, nivolumab is associated with the highest rate of 
progressive disease as the best response — about 35% of 
cases compared with only 12% treated with cabozantinib. 
This suggest that nivolumab may not be an optimal choice 
for symptomatic patients or those in whom moderate pro-
gression may be life threatening. As mentioned previously, 
nivolumab might also be less active in elderly patients (> 
75 years old) and in patients with cachexia [24].
Compared with everolimus, nivolumab is character-
ised by favourable toxicity profile and a beneficial impact 
on quality of life. Direct comparison of its toxicity profile 
with TKI is difficult due to the different methods of safety 
assessment used in each trial. It is well recognised that 
adverse event profiles differ between TKI and immune 
checkpoint inhibitors, and this difference can affect pa-
tients’ and physicians’ treatment preferences. 
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Table 5. Comparison of activity of drugs used in the second-line treatment of renal cell carcinoma after progression on 
tyrosine kinase inhibitors aimed at VEGF
Axitinib [40] Everolimus [27, 28] Cabozantinib [41] Nivolumab [27, 28]
mOS (months) 20.1 19.7 21.4 25.8
mPFS (months) 8.3 4.5 7.4 4.2
ORR (CR + PR) 19% 5% 17% 26%
CBR (CR + PR + SD) 76% 61% 87% 59%
PD as best response 17% 28% 12% 35%
CBR — clinical benefit rate; mOS — median overall survival; mPFS — median progression-free survival; ORR — objective response rate; CR — complete re-
sponse; PR — partial response; SD — stable disease; PD — progressive disease
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Figure 3. Trends in recruitment in trials assessing combination of immunotherapy with other therapies (based on [12])
Concluding, second-line treatment of advance RCC 
with nivolumab can be considered in patients: under 
75 years old; optimally asymptomatic or mildly sympto-
matic; without critical tumour mass; without significant 
cachexia; and capable of withstanding autoimmunological 
adverse events (e.g. without contraindication to steroids). 
Future of immuno-oncology 
— perspectives for innovative 
combinational therapies
Comparison of toxicity profile of anti-PD1 and an-
ti-PD-L1 immunotherapies and their comparators with-
in clinical trials strongly favours immunotherapy [32]. 
Low toxicity and increased activity, as well as potential 
synergy of combinational therapy, encourage research 
assessing combinations of both immuno-oncologic 
drugs and immunotherapy with other anticancer thera-
pies and treatment modalities.
These and other factors result in growing numbers 
of studies dedicated to combinational therapies (Fig. 3). 
Between 2014 and 2017 the number of new clinical tri-
als assessing immunotherapy combinations increased 
eight-fold and the number of recruited patients over 
four-fold [12]. As a result, a trend towards reduced 
population size in trials can be seen, probably due to 
several factors, including large numbers of innovative 
combinational therapies assessed in early phases on 
limited populations, and improved selection of patients 
in more advanced trials that enable sufficient statistical 
power with lower numbers of patients per trial. 
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It is difficult to predict when trial results will be 
published because this is affected by numerous factors: 
recruitment time; assessed end-points; pace of matur-
ing data; sources of financing; and others. According 
to a large analysis performed by American researchers 
the estimated median time from recruitment closure to 
publication is about 47 months – nearly four years [33]. 
Assuming that the recruitment for trials presented in 
Figure 3 require 12 months on average, we may estimate 
that half of the trials initiated in 2014 will be published 
before 2020. Moreover, based on this calculation, we 
may anticipate results from over 500 trials assessing 
immunotherapy combination in the next five years. 
Summary
The immunological system is a key component of 
both pathogenesis and treatment of RCC. Understand-
ing of complex mechanisms that take part in activation 
and in effector phase of adaptive cellular immune 
response allows the development of more efficient 
therapies and leads to their effective implementation 
in clinical practice.
Nivolumab acts mostly through modification of the 
effector phase of immune response. It proved activity in 
several cancer types, becoming the standard of care in 
many. As the number of patients potentially qualifying 
for treatment with immune checkpoint inhibitors grows, 
so should the knowledge regarding their strong and 
weak points, subpopulations with increased or decreased 
treatment efficiency, and about their interactions with 
other therapies. 
European patients with renal cell carcinoma may be 
treated with nivolumab after failure of at least one line 
of prior systemic therapy*. Nivolumab offers promising 
activity in terms of response rate and median overall 
survival, along with a favourable toxicity profile. Unfor-
tunately, nivolumab is limited by high rates of primary 
resistance and decreased activity in older patients and 
in the presence of cachexia. 
A large number of new trials assessing immunothera-
py in combinations with other therapies is a consequence 
of encouraging results achieved with immune checkpoint 
monotherapy. Analysis of trends in numbers of such 
trials gives hope that the best in immuno-oncology is 
yet to come. 
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